Business

Pfizer Scraps Allergan Deal amid US Tax Law Change

Pharmaceutical company Pfizer has scrapped a planned merger with Ireland’s Allergan amid plans to change US tax laws.

The decision comes two days after the US Treasury announced fresh plans to prevent deals known as “inversions”, where a US company merges with another company in a country with a lower tax rate.

The Pfizer-Allergan deal, valued at $160 billion, would have been the biggest example of an “inversion”.

It would also have been the biggest pharmaceutical deal in history.

Pfizer said the move was “driven by the actions announced” by the US Treasury.

The company’s chairman and chief executive Ian Read said: “Pfizer approached this transaction from a position of strength and viewed the potential combination as an accelerator of existing strategies.”

He added that the company could look at splitting off part of the business.

“We plan to make a decision about whether to pursue a potential separation of our innovative and established businesses by no later than the end of 2016, consistent with our original timeframe for the decision prior to the announcement of the potential Allergan transaction.”

Pfizer said it would pay Botox-maker Allergan $150 million “for reimbursement of expenses associated with the transaction”.

Under the proposed acquisition, Pfizer would have moved its headquarters to Dublin, where the tax bill would have been lower than in the US.

The corporation tax rate in the Republic of Ireland is 12.5%, compared with 35% in the US.

On April 5, President Barack Obama weighed in on the inversion trend, saying “these companies get all the rewards of being an American company without fulfilling their responsibility to pay their fair share of taxes”.

In 2014, American fast-food chain Burger King bought Canadian coffee and doughnut chain, Tim Hortons. The merged group moved to Ontario in Canada, where the corporate tax rate is at 26.5%.

Analysts had said that Pfizer needed to look at acquisitions to help grow its business and revenue.

Pfizer made an offer to buy UK drugs group AstraZeneca in 2014.

However, AstraZeneca rejected the offer, arguing it undervalued the company.

Clyde K. Valle

Clyde is a business graduate interested in writing about latest news in politics and business. He enjoys writing and is about to publish his first book. He’s a pet lover and likes to spend time with family. When the time allows he likes to go fishing waiting for the muse to come.

Recent Posts

Quincy Jones Dead at 91

Quincy Jones, the celebrated musician and producer who worked with Michael Jackson, Frank Sinatra, Ray…

7 hours ago

White House 2024: Voter Fraud Claims Flood Social Media

Misleading allegations, rumours and outright lies about voting and fraud are flooding online spaces in…

2 days ago

Spain: At Least 158 Killed In The Country’s Worst Flooding Disaster

At least 158 people have died in Spain's worst flooding disaster in generations. On October…

4 days ago

Russia Fines Google $20,000,000,000,000,000,000,000,000,000,000,000, Surpassing Global GDP

Google has been fined two undecillion (a two followed by 36 zeroes) roubles by a…

4 days ago

Financing Your Home Remodel: 7 Tips for Success

Embarking on a home remodel is an exciting journey, promising enhanced comfort, increased property value,…

2 weeks ago

Donald Trump Serves Up McDonald’s Fries While Kamala Harris Celebrates 60th Birthday with Church Choir

The US presidential candidates continued to campaign across key swing states on October 20. Footage…

2 weeks ago